Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact
photo

University City Science Center Bootcamp, Philadelphia, USA

March 7th 2022February 14th 2020

Read More

photo

J.P. Morgan Annual Healthcare Conference, San Francisco, USA

March 7th 2022January 10th 2020

Read More

Photo

Sharon and Orlaith featured in the Irish Times Top 50 people to watch in 2020

April 18th 2021January 4th 2020

Read More

Photo

Shorla Oncology featuring in Enterprise Ireland and the Local Enterprise Offices ‘Start’ campaign

March 7th 2022September 24th 2019

Read More

Banner

DCAT New York City, USA

March 7th 2022March 15th 2019

Read More

Photo

Biotech Showcase at J.P. Morgan Annual Healthcare Conference, San Francisco, USA

March 7th 2022January 4th 2019

Read More

Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

STATE COMPLIANCE PROGRAM DECLARATIONS

Company number: 618033
©SHORLA ONCOLOGY® 2026

© 2026 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.